Search Results - "Segui, M A"

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study by Alba, E., Chacon, J. I., Lluch, A., Anton, A., Estevez, L., Cirauqui, B., Carrasco, E., Calvo, L., Segui, M. A., Ribelles, N., Alvarez, R., Sanchez-Muñoz, A., Sanchez, R., Garcia-Asenjo, J. A. Lopez, Rodriguez-Martin, C., Escudero, M. J., Albanell, J.

“…Chemotherapy remains as the only systemic treatment option available for basal-like breast cancer (BC) patients. Preclinical models and several phase II…”
Get full text

Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain by Font, R, Espinas, J A, Gil-Gil, M, Barnadas, A, Ojeda, B, Tusquets, I, Segui, M A, Margelí, M, Arcusa, A, Prat, A, Garcia, M, Borras, J M

“…Aims: To compare different methods in order to assess adherence and persistence with oral endocrine therapy in women diagnosed with breast cancer (BC) in…”
Get full text

Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors by Travier, N., Fonseca-Nunes, A., Javierre, C., Guillamo, E., Arribas, L., Peiró, I., Buckland, G., Moreno, F., Urruticoechea, A., Oviedo, G. R., Roca, A., Hurtós, L., Ortega, V., Muñoz, M., Garrigós, L., Cirauqui, B., del Barco, S., Arcusa, A., Seguí, M. A., Borràs, J. M., Gonzalez, C. A., Agudo, A.

“…Energy restriction from a low-calorie diet and increased energy expenditure induced by physical activity (PA) could promote weight loss/maintenance and be…”
Get full text

Infiltrating ductal carcinoma: infiltrates at the exit site of a central venous access port device by Moya Horno, I., Fernández Morales, L.A., Dalmau Portulas, E., Seguí Palmer, M.A., Font Renom, J., Aparicio Rodríguez, O., Falcó Fages, J., Querol Niñerola, R., Pampols Felip, M., Saigí Grau, E.

Get full text

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen by Martín, M., Lluch, A., Seguí, M. A., Ruiz, A., Ramos, M., Adrover, E., Rodríguez-Lescure, Á., Grosse, R., Calvo, L., Fernandez-Chacón, C., Roset, M., Antón, A., Isla, D., del Prado, P. Martínez, Iglesias, L., Zaluski, J., Arcusa, A., López-Vega, J. M., Muñoz, M., Mel, J. R.

“…Background: The aim of the study was to analyse the toxicity and health related quality of life (HRQoL) of breast cancer patients treated with FAC…”
Get full text

SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016) by Muñoz, M., Santaballa, A., Seguí, M. A., Beato, C., de la Cruz, S., Espinosa, J., Fonseca, P. J., Perez, J., Quintanar, T., Blasco, A.

“…Chemotherapy and radiotherapy often result in reduced fertility in cancer patients. With increasing survival rates, fertility is an important quality-of-life…”
Get full text

Fulvestrant plus LHRH analogues in male with synchronous breast and prostate cancer by Martinez Vila, C., Fernández-Morales, L.A., Oliveres, H., Marín, M., Ribera, P., Pardo, J.C., Dalmau, E., Segui, M.A.

Get full text

Situation, challenges, and SEOM recommendations for the future of undergraduate education in Oncology in Spain by Segui, M. A., Cruz, J. J., Alba, E., Feliu, J., Jara, C., Rivera, F., Rodriguez Lescure, A., Lorenzo, A., Martin, M.

“…Purpose The Spanish Society of Medical Oncology (SEOM, for its Spanish acronym) would like to attest to the relevance of training in Oncology as part of the…”
Get full text

Exercise and cancer: a position statement from the Spanish Society of Medical Oncology by Pollán, M., Casla-Barrio, S., Alfaro, J., Esteban, C., Segui-Palmer, M. A., Lucia, A., Martín, M.

“…Due to improvements in the number of cancer survivors and survival time, there is a growing interest in healthy behaviors, such as physical activity (PA), and…”
Get full text

Role of boost radiotherapy for local control of pure ductal carcinoma in situ after breast-conserving surgery: a multicenter, retrospective study of 622 patients by Cambra, M. J., Moreno, F., Sanz, X., Anglada, L., Mollà, M., Reyes, V., Arenas, M., Pedro, A., Ballester, R., García, V., Casals, J., Cusidó, M., Jimenez, C., Escribà, J. M., Macià, M., Solé, J. M., Arcusa, A., Seguí, M. A., Gonzalez, S., Farrús, B., Biete, A.

“…Purpose To evaluate the effect of boost radiotherapy on ipsilateral breast tumor recurrence (IBTR) for ductal carcinoma in situ (DCIS) after breast-conserving…”
Get full text

Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study by Antón, A., Ruiz, A., Plazaola, A., Calvo, L., Seguí, M.A., Santaballa, A., Muñoz, M., Sánchez, P., Miguel, A., Carrasco, E., Lao, J., Camps, J., Alfaro, J., Antolín, S., Cámara, M.C.

“…Background: We previously reported a phase I trial of liposome-encapsulated doxorubicin citrate (LD), docetaxel and trastuzumab as neoadjuvant in stages II and…”
Get full text

Finding the right dose of fulvestrant in breast cancer by Estévez, L, Alvarez, I, Tusquets, I, Seguí, M.A, Muñoz, M, Fernández, Y, Lluch, A

“…Abstract Fulvestrant is a selective estrogen receptor downregulator, behaving as a complete antagonist. It was initially approved, at a dose of 250 mg, to…”
Get full text

p53 oncoprotein as a prognostic indicator in patients with breast cancer by Molina, R, Segui, M A, Climent, M A, Bellmunt, J, Albanelll, J, Fernandez, M, Filella, X, Jo, J, Gimenez, N, Iglesias, E, Miralles, M, Alonso, C, Peiro, G, Perez-Picañol, E, Ballesta, A M

“…p53 is a tumor suppressor gene located on the human chromosome 17 that is thought to regulate (suppress) the proliferation of normal cells. The mutant protein…”
Get more information

Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study by Antón, A., Ruiz, A., Seguí, M. A., Calvo, L., Muñoz, M., Lao, J., Sancho, F., Fernández, L.

“…Background: We carried out a phase I clinical trial to establish the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of the combination of…”
Get full text

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response by Sánchez-Rovira, P., Seguí, M. A., Llombart, A., Aranda, E., Antón, A., Sánchez, A., Lomas, M., Jaén, A., Fernández, M., Porras, I., Dalmau, E., Morales, S., de la Haba-Rodríguez, J.

“…Purpose The primary aim of this trial was to assess the rate of pathologic complete responses (pCR) of doxorubicin/cyclophosphamide (AC) followed by…”
Get full text

HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer—A study of two hundred cases by Sáez, A., Andreu, F.J., Seguí, M.A., Baré, M.L., Fernández, S., Dinarés, C., Rey, M.

“…The purpose of the study was to compare two methods used to analyse HER-2 gene amplification (fluorescence in situ hybridisation (FISH) and chromogenic in situ…”
Get full text

Complete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens by Marin Alcala, M., Llort Pursals, G., Del Riego Ferrari, J.H., Giner, J., Andreu Navarro, F.X., Medina, S., Aparicio, O., Dalmau Portulas, E., Ribera Fernandez, P., Oliveres, H., Martinez Vila, C., Cabrera Romero, J.M., Segui Palmer, M.A., Fernandez Morales, L.A.

Get full text

Clinical experience with tegafur and low dose oral leucovorin: a dose-finding study by Nogué, M, Saigí, E, Seguí, M A

“…Tegafur is an effective oral fluoropyrimidine that shows the same activity as 5-fluorouracil for a similar spectrum of cancers. Their biochemical modulation…”
Get more information

SEOM clinical guidelines in advanced and recurrent breast cancer (2018) by Chacón López-Muñiz, J. I., de la Cruz Merino, L., Gavilá Gregori, J., Martínez Dueñas, E., Oliveira, M., Seguí Palmer, M. A., Álvarez López, I., Antolin Novoa, S., Bellet Ezquerra, M., López-Tarruella Cobo, S.

“…Although the metastasic breast cancer is still an incurable disease, recent advances have increased significantly the time to progression and the overall…”
Get full text

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition by Mateo, F, Arenas, E J, Aguilar, H, Serra-Musach, J, de Garibay, G Ruiz, Boni, J, Maicas, M, Du, S, Iorio, F, Herranz-Ors, C, Islam, A, Prado, X, Llorente, A, Petit, A, Vidal, A, Català, I, Soler, T, Venturas, G, Rojo-Sebastian, A, Serra, H, Cuadras, D, Blanco, I, Lozano, J, Canals, F, Sieuwerts, A M, de Weerd, V, Look, M P, Puertas, S, García, N, Perkins, A S, Bonifaci, N, Skowron, M, Gómez-Baldó, L, Hernández, V, Martínez-Aranda, A, Martínez-Iniesta, M, Serrat, X, Cerón, J, Brunet, J, Barretina, M P, Gil, M, Falo, C, Fernández, A, Morilla, I, Pernas, S, Plà, M J, Andreu, X, Seguí, M A, Ballester, R, Castellà, E, Nellist, M, Morales, S, Valls, J, Velasco, A, Matias-Guiu, X, Figueras, A, Sánchez-Mut, J V, Sánchez-Céspedes, M, Cordero, A, Gómez-Miragaya, J, Palomero, L, Gómez, A, Gajewski, T F, Cohen, E E W, Jesiotr, M, Bodnar, L, Quintela-Fandino, M, López-Bigas, N, Valdés-Mas, R, Puente, X S, Viñals, F, Casanovas, O, Graupera, M, Hernández-Losa, J, Ramón y Cajal, S, García-Alonso, L, Saez-Rodriguez, J, Esteller, M, Sierra, A, Martín-Martín, N, Matheu, A, Carracedo, A, González-Suárez, E, Nanjundan, M, Cortés, J, Lázaro, C, Odero, M D, Martens, J W M, Moreno-Bueno, G, Barcellos-Hoff, M H, Villanueva, A, Gomis, R R, Pujana, M A

“…Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive…”
Get full text